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Abstract
Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine malignancy of the skin characterized by high
aggressiveness. Four main factors are implicated in its development: immunosuppression, ultraviolet radiation, age
and the Merkel cell polyomavirus (MCPyV). In recent years, immune checkpoint inhibitors have shown clinical
activity in MCC treatment.
Case presentation: We report the case of an 82-year-old man with a lung adenocarcinoma diagnosis, who
underwent immunotherapy with nivolumab as second-line treatment. Seven months after the diagnosis of lung
cancer during the nivolumab treatment, the patient developed an eyelid MCC, initially misdiagnosed as a chalazion.
A palliative radiotherapy was performed with clinical benefit. After a total of seven cycles of nivolumab, computed
tomography showed a lung and cerebral disease progression. In addition, clinical conditions worsened leading to
the patient’s death 13 months after the initial lung cancer diagnosis.
Conclusions: Cases of co-occurrence of MCC and non-small cell lung cancer (NSCLC) have rarely been reported.
Interestingly, common risk factors may be postulated for both cancers. Considering the rarity of this adverse event,
its short-term temporal relation with the administration of the drug, which makes a relation improbable, and the
coexistence of other risk factors, which may provide plausible explanations, it is possible to conclude according to
the WHO Adverse Reaction Terminology that a causal relation between the occurrence of this serious adverse
event and the exposure to the drug is unlikely. However, the case deserves to be reported in the literature.
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Background
Merkel cell carcinoma (MCC) is a rare neuroendocrine
malignancy of the skin characterized by a high aggres-
siveness with an overall survival of 10 months in the
metastatic setting [1, 2]. It is an age-related cancer with
a higher incidence in elderly patients. Historically, the
two main factors implicated in the onset of MCC were
exposure to ultraviolet rays and immunosuppression [3].
In 2008 Feng et al. revealed a new polyomavirus, until
then unknown, in MCC tissue samples - the Merkel cell
polyomavirus (MCPyV) [4]. Several studies have shown
that MCPyV-DNA is integrated into tumor cells in
about 80% of MCC cases, inferring that infection plays
an important role in the pathogenesis of MCC [4, 5].
About a half of all MCCs originate from the head and
neck (H&N) area. 5–20% of the H&N MCCs originate in
the eyelids [6]. In most cases, the lesion is rapidly evolving
and the diagnosis is not always readily identified. In fact, the
lesion is often misdiagnosed as a chalazion or a stye [6, 7].
MCC shows very low response rates to cytotoxic
chemotherapy [8–10]. In recent years, immune check-
point inhibitors such as avelumab, an anti-programmed
death ligand 1 (PD-L1) monoclonal antibody (MoAb),
pembrolizumab and nivolumab, anti-programmed death
1 (PD-1) MoAbs, have shown clinical activity in the
treatment of MCC. [11–16]. On March 23, 2017, the
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U.S. Food and Drug Administration granted accelerated
approval to avelumab for the treatment of patients with
metastatic MCC [11].
Case presentation
We report the case of an 82-year-old man, who under-
went a total body computed tomography (CT) on Febru-
ary 2017, due to the occurrence of cough. CT showed an
extensive mass in the left upper lobe of the lung. Thus, a
bronchoscopy with transbronchial needle aspiration
(TBNA) was performed. The cytological examination
was compatible with lung adenocarcinoma. Epidermal
growth factor receptor (EGFR) mutations and anaplastic
lymphoma kinase (ALK) translocation were tested to de-
termine the most appropriate treatment but no mutation
was detected. It was not possible to test PD-L1 expres-
sion because only cytological samples were available.
To complete the staging of the disease, the patient
underwent a positron emission tomography (PET) exam-
ination. PET showed a massive tracer uptake at the pul-
monary mass and showed an extensive involvement of
the hilar and mediastinal lymph nodes. Before starting
the treatment, a further TC scan was performed in May.
TC showed an increased pulmonary mass involving ap-
proximately the entire left lung.
The patient referred a smoking history and as comorbidi-
ties: arterial hypertension, osteoporotic and traumatic verte-
bral fractures, iatrogenic bone marrow lesion resulting
from surgery for discopathy, benign prostatic hypertrophy
treated with transurethral resection, pulmonary emphy-
sema, carotid vasculopathy and abdominal aneurysm. He
had an ECOG performance status of 2.
In relation to clinical conditions, age and comorbidi-
ties, the patient underwent two chemotherapy cycles
with oral vinorelbine (day 1,8 every 21), the latter of
which was administered in July. During the treatment,
the patient experienced fatigue G1, diarrhea G1, consti-
pation G1, anorexia G1 and hyperkinetic supraventricu-
lar arrhythmia treated with amiodarone.
The restaging CT was performed in July and showed
lung disease progression. Thus, from July to December,
the patient received 3 mg/kg nivolumab (day 1 every 14)
as second-line treatment for a total of seven cycles.
Based on body weight, nivolumab was administered at a
dose of 195 mg for the first two cycles and 205 mg for
the subsequent five cycles. After the first two doses, the
patient was hospitalized at the emergency department
with a diagnosis of pneumonia. Therefore, antibiotics
and corticosteroids were administered and a clinical im-
provement was obtained. In September, the patient re-
covered a good respiratory performance, so he was able
to restart nivolumab. The subsequent five cycles were
well tolerated except for grade 1 hypothyroidism and
grade 2 fatigue.
Collaterally, in September, the patient showed a small
nodular dome shaped lesion on the upper eyelid. He
consulted a private ophthalmologist who initially sus-
pected a diagnosis of chalazion. However, the lesion in-
creased until about 3 cm within a few weeks. Thus, the
patient came back to the Ophthalmology Department of
Azienda Ospedaliera-Universitaria Careggi of Florence
where a biopsy was performed, with the suspect of a ma-
lignant lesion. The histological examination indicated an
MCC (immunohistochemical study: cytokeratin 20+,
synaptophysin+, chromogranin+, CD20-, CD3-, Ki67
60–70%) (Fig. 1).
A nuclear magnetic resonance imaging of the orbit
and neck did not show lymph node involvement.
The case was collegially discussed. Since the patient
was at high risk for anesthesia due to his clinical condi-
tions and given the prognosis of lung cancer, surgery
was contraindicated. Thus, a palliative radiotherapy was
proposed and was started in December when the lesion
had expanded to about 5 cm in the anteroposterior
diameter. Following radiotherapy, the size of the eyelid
lesion was reduced to a few millimeters.
In December 2017, after a total of seven cycles of nivo-
lumab, a CT scan was also performed. It showed a lung
and cerebral disease progression. In addition, there was
a worsening of clinical conditions with increased cough
and fatigue. Therefore, the best supportive care was pro-
vided until the patient died in March 2018.
Discussion and conclusions
Our patient developed an eyelid MCC 7 months after
the diagnosis of lung cancer. Available data in literature
shows that, overall, there is no statistically significant
risk to develop an MCC following a diagnosis of primary
lung cancer (i.e. standardized significant rate (SIR) 0.88;
95% CI 0.32–1.92), as well as to develop an MCC within
1 year from the diagnosis of lung cancer ((SIR) 0.63; 95%
CI 0.13–1.85) [17].
The development of MCC occurred during a treat-
ment with nivolumab for a lung adenocarcinoma. Nivo-
lumab is a fully human IgG4 immune checkpoint
inhibitor antibody targeting PD-1 that has been ap-
proved for the treatment of advanced or metastatic
non-squamous non-small-cell lung cancer (NSCLC) ac-
cording to positive results of the phase III, open label
study CheckMate 057 [18].
An analysis of the literature was performed to know
whether any MCC occurrences in the course of a nivolu-
mab treatment had been reported. The research did not
identify any publications related to the occurrence of MMC
during nivolumab treatments. Based on post-marketing re-
ports of the nivolumab producer, one case of neuroendo-
crine carcinoma during the treatment with this drug for
lung adenocarcinoma has been described. However, since
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this type of event is reported voluntarily from a population
of uncertain size, it is generally not possible to reliably esti-
mate the frequency or to establish a causal relationship to
the drug exposure.
MCC represents a checkpoint inhibitor responsive
cancer. Factors that have been suggested to contribute
to an immunotherapy response are represented by a
high tumor mutational burden due to the ultraviolet rays
exposure [19] and the integration of MCPyV DNA se-
quence. In fact, high expression levels of inhibitory re-
ceptors such as PD-1 and Tim-3 have been found on
MCC infiltrating lymphocytes and T CD8-specific
MCPyV cells [5]. These factors offer a rationale for treat-
ing patients with anti PD-1/anti PD-L1 monoclonal
antibodies.
Avelumab is indicated in the treatment of MCC based
on an open-label, single-arm, multi-center clinical trial
(JAVELIN Merkel 200 trial). It induced an objective re-
sponse (OR) in 33% of treated patients [11]. Responses to
avelumab were observed irrespective of PD-L1 expression
on tumor cells or Merkel cell polyomavirus status [12].
In a multicentre phase 2 noncontrolled trial including
26 patients with an advanced MCC pembrolizumab in-
duced an OR in 56% of patients. PD-L1 expression was
more frequent in MCPyV-positive cancers than in
MCPyV-negative cancers (71% vs 25%). Responses were
observed in both virus-positive and virus-negative. No
significant correlation of PD-L1 expression on tumor
cells or infiltrating immune cells with drug response was
observed [13].
A significant and durable response in a patient with
metastatic MCC following nivolumab therapy was re-
ported [14]. Preliminary results of an ongoing non-
comparative, multiple cohort, open-label, phase 1/2
study (CheckMate 358) of nivolumab in patients (n = 50
MCC) with virus-positive and virus-negative solid tu-
mors show an OR in 64% of advanced MCC cases and
pathologic tumor regressions in 65% of resectable MCC
cases [15, 16]. Moreover, a phase 2 clinical trial evaluat-
ing nivolumab + ipilimumab +/− stereotactic body radi-
ation therapy (SBRT) for metastatic MCC is ongoing
(NCT03071406).
Four main factors are implicated in the development
of MCC: immunosuppression [20–25], ultraviolet radi-
ation [3], age [26], and MCPyV [4, 5]. Overall, our pa-
tient presented three out of four MCC risk factors,
whereas the MCPyV positivity status was unknown.
As far as immunosuppression is concerned, it is
known that immunosuppressed patients have a poor
prognosis with a reduced MCC-specific survival [20].
Immunosuppressive conditions determining an in-
creased risk of developing an MCC are: patients with
haematological malignancies, especially chronic lympho-
cytic leukaemia [21, 22], acquired immunodeficiency
syndrome (AIDS) [23], patients undergoing organ trans-
plantation [24] or patients in chronic treatment for auto-
immune diseases [25]. Our patient did not have an
immunosuppressive state such as those described above,
but he had a lung cancer and he previously had received
chemotherapy with vinorelbine.
Fig. 1 Histological examination. a Hematoxylin-eosin (20×); b Hematoxylin-eosin (40×); c Ki67 (10×); d Cytokeratin 20 (20×); e Chromogranin
(20×); f Synaptophysin (20×)
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It is also well known that there is a strong association be-
tween MCC and a history of sun exposure [3].
Ultraviolet-associated mutations in RB1, TP53, NOTCH1
and FAT1 genes have been reported in MCPyV-negative
cancers [19]. In our patient, the MCC developed in one of
the most sun-exposed anatomical sites, so prolonged ex-
posure to ultraviolet light may have been a relevant causal
factor of the MCC. On the basis of the information gained
by the anamnestic collection, a history of high sun exposure
both before and during the treatments was highlighted.
Regarding age, it has been shown that H&N MCCs
have a higher incidence in elderly patients. It is known
that MCPyV seroprevalence increases according to age
achieving 73% in subjects older than 70 years [26].
Our patient had two cancers in which MCPyV has
been proposed to be related with the pathogenesis. In
fact, several studies have reported the presence of
MCPyV-DNA integrated into tumor cells in about 80%
of MCC cases [4, 5] and in a range from 9 to 18% in
NSCLCs [27–29]. Thus, although the underlying tumori-
genic mechanisms are unknown, in a subset of patients
MCPyV could play an important role also in the patho-
genesis of NSCLC, through the expression of two puta-
genic oncoproteins (i.e. large T and small T antigens)
[29, 30]. Unfortunately, we were not able to determine
the presence of MCPyV DNA due to the unavailability
of biological material. However, it must be noted that al-
though MCC is a rare cancer, MCPyV is ubiquitous in
human populations (i.e. from 60 to 80% of the general
population is infected with MCPyV) [30].
In conclusion, we described a case of eyelid MCC oc-
curring in a patient with recent diagnosis of NSCLC
during second-line treatment with nivolumab. Cases of
co-occurrence of MCC and NSCLC have rarely been re-
ported. Interestingly, common risk factors may be postu-
lated for both cancers. Considering the rarity of this
adverse event, its short-term temporal relation with the
administration of the drug, which makes a relation im-
probable, and the coexistence of other risk factors,
which may provide plausible explanations, it is possible
to conclude according to the WHO Adverse Reaction
Terminology [31] that a causal relation between the oc-
currence of this serious adverse event and the exposure
to the drug is unlikely. However, the case deserves to be
reported in the literature.
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